In the further analysis, the respondents having history of chronic headache have 5 times high risk of contracting COVID-19 (AoR 5.66, 95%CI: 3.007-10.688; p<0.001) compared to the respondents not having history of not having chronic headache. The similarity was also highlighted in the study on risk factors in association with the severe COVID-19 infectivity in a region of Amazon, where headache represented 24.5% of 24,671 confirmed patients (Daniele et al., 2021).

REFERENCES

Adhikari et al. (2020). Epidemiology , causes , clinical manifestation and diagnosis , prevention and control of coronavirus disease (COVID-19) during the early outbreak period : a scoping review. pp. pp. 1–12.

Al-Hazmi, A. (2016). Challenges presented by MERS corona virus, and SARS corona virus to global health. *Saudi journal of biological sciences*, 23 (4):507–11.

Andreia Leite et al. (2021). A Case- Control study of contextual factors for SARS-CoV-2 transmission. *Front Public Health*, (9): 1-10.

Arabi, et al. (2018). Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome. *Am J Respir Crit Care Med*, 197 (6):757–67.

Arabi, et al. (2019). Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: a Multicenter Observational Study. *Clin Infect Dis*.

Arentz, et al. (2020). Characteristics and outcomes of 21 critically Ill patients with COVID-19 in Washington State. *JAMA*.

Bernheim, et al. (2020). Chest CT Findings in Coronavirus Disease-19 (COVID-19): Relationship to Duration of Infection. *Radiology*, 200463.

Bhatraju, et al. (2020). Covid-19 in critically Ill patients in the Seattle region-case series. *N Engl J Med*.

Bi, et al. (2020). *Epidemiology and Transmission of COVID-19 in Shenzhen China: Analysis of 391 cases and 1,286 of their close contacts.*

Blaising, J., Polyak, S., & Pécheur, E. (2014). Arbidol as a broad-spectrum antiviral: an update. *Antiviral Res*, 107 :84–94.

Booth, et al. (2003). Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. *JAMA*, 289 (21):2801–9.

Cao, et al. (2020). A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. *N Engl J Med*.

Carinci, F. (2020). Covid-19: preparedness, decentralisation, and the hunt for patient zero. *BMJ*, 368 bmj.m799-bmj.m799.

Cascella, et al. (2020). Features, Evaluation and Treatment Coronavirus (COVID-19) . *StatPearls*.

Chen , et al. (2020). Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19. *Zhonghua xin xue guan bing za zhi* , 48 (0) E0 08-E0 08.

Chen , et al. (2020). Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. *Lancet (London, England)*, 395 (10226):809–15.

Chen, et al. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*, 395 (10223):507–13.

Cheng, Z., & Shan, J. (2020). 2019 Novel coronavirus: where we are and what we know. *Infection* , doi: 10.1007/s15010- 020- 01401- y.

Citrawati Dyah Kencono Wungu et al., Meta-analysis of cardiac markers for predictive factors on severity and mortality of COVID-19. *Int J Infect Dis 105(2021) 551-559*

Collins, B.-A. (2020, October 13). *Social, environmental factors seen behind Africa's low COVID-19 cases*. Retrieved from Reliefweb: https://reliefweb.int/report/south-africa/social-environmental-factors-seen-behind-africa-s-low-covid-19-cases

Colson, P., & Raoult, D. (2016). Fighting viruses with antibiotics: an overlooked path. *Int J Antimicrob Agents*, 48 (4):34 9–52.

Corman, et al . (2020). Detection of 2019 novel coronavirus (2019-nCoV) by real-time ime RT-PCR. Euro surveillance: bulletin Europeen sur les maladies transmissibles. *European communicable disease bulletin*, 25 (3):20 0 0 045 .

Dai, et al. (2020). CT Imaging and Differential Diagnosis of COVID-19. *Canadian Association of Radiologists journal=Journal l'Association canadienne des radiologistes*, 846537120913033-846537120913033.

Deng, et al. (2020). Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019:a retrospective cohort study.Corona Virus Disease 2019:a retrospective cohort study. *J Infect*, pii:S0163-4453(20)30113-4.

Fang, et al. (2020). Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR. *Radiology*, 200432.

Fateneh S et al. (2020). Predisposing risk factors for COVID-19 infection: A case-control study. *Caspian J Intern Med*, 11(1) 496-500

Gao, Q., Chen, Y., & Fang, J. (2020). 2019 novel coronavirus infection and gastrointestinal tract. *J Digest Dis* , doi: 10.1111/1751-2980.12851.

.Gottfredsson, M. (2008). The Spanish flu in Iceland 1918. Lessons in medicine and history. *Laeknabladid*, 94 (11):737–45.

Han, et al. (2020). Early Clinical and CT Manifestations of Coronavirus Disease 2019 (COVID-19) Pneumonia. *AJR Am J Roentgenol*, 1–6.

Holshue,et al. (2020). First Case of 2019 Novel Coronavirus in the United States. *N Engl J Med*, 382 (10):929–36.

Huang, et al. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. 497-506.

Huilan, et al. (2020). Review: Current epidemiological and clinical features of COVID-19; a global. *Journal of Infection*, 81:1–9.

Jefferson, et al. (2014). Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. *BMJ*, 348 :g2545.

Jiehao, C., Xu, J., Lin, D., Yang, Z., Xu, L., & Qu, Z. (2020). A Case Series of children with 2019 novel coronavirus infection: clinical and epidemiological features. *Clin Infect Dis,* ciaa198.

Kadam, R., & Wilson, I. (2017). Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol. *Proc Natl Acad Sci USA*, 114 (2):206–14.

Kartika et al. (2017). Risk factor of severe preeclampsia in Dr. Soetomo HospitalSurabaya in 2015 . *Majalah Obstetri Ginekologi*, 25, 6–9.

Khan et al. (2020). The emergence of a novel coronavirus (SARS-CoV-2), their biology and therapeutic options. *J Clin Microbiol*, pii: JCM.00187-20.

Koren , et al. (2003). Ribavirin in the treatment of SARS: a new trick for an old drug? *CMAJ,* 168 (10):1289–92.

Lau, et al. (2020). The positive impact of lockdown in Wuhan on containing the COVID-19 outbreak in China. *J Travel Med*, pii: taaa037.

Lee, Y., & Lee, C. (2016). Ivermectin inhibits porcine reproductive and respiratory syndrome virus in cultured porcine alveolar macrophages. *Arch Virol*, 161 (2):257–68.

Li, et al. (2020). Development and Clinical Application of A Rapid IgM-IgG Combined Antibody Test for SARS-CoV-2 Infection Diagnosis. *J Med Virol* , doi: 10.1002/jmv.25727.

Li, Y., & Xia, L. (2020). Coronavirus Disease 2019 (COVID-19): Role of Chest CT in Diagnosis and Management. *AJR Am J Roentgenol*, 1–7.

Lu, H. (2020). Drug treatment options for the 2019-new coronavirus (2019-nCoV). *Biosci Trends*, 14 (1):69–71.

MacIntyre, C., & Chughtai, A. (2015). Facemasks for the prevention of infection in healthcare and community settings. *BMJ*, 350 h694-h694.

Martinez, M. (2020). Compounds with therapeutic potential against novel respiratory 2019 coronavirus. *Antimicrob Agents Chemother*, pii: AAC.00399-20.

Mbakaya, B., Lee, P., & Lee, R. (2017). Hand hygiene intervention strategies to reduce diarrhoea and respiratory infections among schoolchildren in developing countries: a systematic review. *Int J Environ Res Public Health*, 14 (4):371.

McQuade, B., & Blair, M. (2015). Influenza treatment with oseltamivir outside of labeled recommendations. *Am J Health Syst Pharm*, 72 (2):112–16.

MOH [Rwanda]. (2020). *Home Based Isolation and Care Guidelines for Patients with COVID-19.* Kigali

MOH [Rwanda]. (2020). *Rwanda Ministry of Health Coronavirus Disease 2019 National Preparedness Response Plan March-August 2020.* Kigali

MOH [Rwanda]. (2020). *Rwanda standard operating procedures for covid-19 outbreak preparedness.* Kigali

MOH [Rwanda]. (2020). *Rwanda standard operating procedures for covid-19 outbreak preparedness, pp. 1–84.* Kigali

Myers, L., Parodi, S., & Liu, V. (2020). Characteristics of hospitalized adults with COVID-19 in an integrated health care system in California. *JAMA*.

Rabie, T., & Curtis, V. (2006). Handwashing and risk of respiratory infections: a quantitative systematic review. *Trop Med Int Health*, 11 (3):258–67.

Rasmussen, et al. (2020). Coronavirus Disease 2019 (COVID-19) and Pregnancy: What obstetricians need to know. *Am J Obstet Gynecol* , S0 0 02-9378(20)30197-6.

Richardson, et al. (2020). Presenting characteristics, Comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. *JAMA.*

Rossignol, J. (2014). Nitazoxanide: a first-in-class broad-spectrum antiviral agent. *Antiviral Res*, 110 :94–103.

Rossignol, J. (2016). Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus. *J Infect Public Health*, 9 (3):227–30.

Rothe , et al. (2020). Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. *N Engl J Med*, 382 (10):970–1.

Rwanda Biomedical Center [RBC]. (2020, October 27). *Public Notice on Novel Coronavirus*. Retrieved from Update on COVID-19 October: https://www.rbc.gov.rw/index.php?id=717

Savarino, et al. (2003). Effects of chloroquine on viral infections: an old drug against today's diseases? . *Lancet Infect Dis*, 3 (11):722–7.

Schwartz, D. (2020). An Analysis of 38 Pregnant Women with COVID-19, Their Newborn Infants, and Maternal-Fetal Transmission of SARS-CoV-2: Maternal Coronavirus Infections and Pregnancy Outcomes. *Arch Pathol Lab Med*.

Schwartz, D., & Graham, A. (2020). Potential Maternal and Infant Outcomes from (Wuhan) Coronavirus 2019-nCoV Infecting Pregnant Women: Lessons from SARS, MERS, and Other Human Coronavirus Infections. *Viruses*, 12 (2):E194.

Shah, J., Peter, N., Kistler, A., Norma, N., Kamm, J., & Lucy, M. (2020). Clinical features, diagnostics, and outcomes of patients presenting with acute respiratory illness: A retrospective cohort study of patients with and without COVID-19 . *EClinicalMedicine*.

Shanmugaraj, et al. (2020). Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). *Asian Pac J Allergy Immunol*.

She, et al. (2020). 2019 novel coronavirus of pneumonia in Wuhan, China: emerging attack and management strategies. *Clin Transl Med*, 9 (1):19.

Song, P., & Karako, T. (2020). COVID-19: Real-time dissemination of scientific information to fight a public health emergency of international concern. *Biosci Trends*, doi: 10.5582/bst.2020.01056.

Song Tang et al (2020). Aerosol transmission of SARS-CoV-2? Evidence, prevention and control. Environment International 144 (2020) 106039

Sun, et al. (2020). Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia. *Zhonghua Jie He He Hu Xi Za Zhi*, 43 (0):E014.

Tchesnokov, et al. (2019). Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir. *Viruses*, 1 (4).

Touret, F., & de Lamballerie, X. (2020). Of chloroquine and COVID-19. *Antiviral Res*, 177 :104762.

Turner, et al. (1986). Prevention of experimental coronavirus colds with intranasal alpha-2b interferon. *J Infect Dis*, 154 (3):443–7.

Tyrrell, D., & Bynoe, M. (1966). Cultivation of viruses from a high proportion of patients with colds. *Lancet*, 1 (7428):76–7.

Varghese, et al. (2016). Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses. *Antiviral Res*, 126 :117–24.

Velavan, T., & Meyer, C. (2020). The COVID-19 epidemic. *Trop Med Int Health*, 25:278–80.

Wang , et al. (2020). Temporal Changes of CT Findings in 90 Patients with COVID-19 Pneumonia: A Longitudinal Study. *Radiology*, 2020:200843.

Wang, et al. (2020). Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*.

Wang, et al. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res*, 30 (3):269–71.

Wang, et al. (2020). Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. *Med Virol*, doi: 10.1002/jmv.25748.

Wang, et al. (2020). Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected Pneumonia in Wuhan, China. *JAMA*.

WHO. (2020, October 04). *Coronavirus disease (COVID-19): Global epidemiological situation. Data as received by WHO from national authorities, as of 04 October 2020, 10 am CEST*. World Health Organization.

WHO. (2020). *Coronavirus disease 2019 (COVID-19) Situtation report," vol. 2019, no. February, 2020*. World Health Organization.

Xia, et al. (2020). Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection. *J Med Virol*, doi: 10.1002/jmv.25725.

Xu, et al. (2020). Management of corona virus disease-19 (COVID-19): the Zhejiang experience]. *Zhejiang Da Xue Xue Bao Yi Xue Ban*, 49 (1) 0 .

Yamamoto, et al. (2016). Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay. *Antimicrob Agents Chemother*, 60 (11):6532–9.

Yang, Y., Shang, W., & Rao, X. (2020). Facing the COVID-19 outbreak: What should we know and what could we do? . *J Med Virol* , doi: 10.1002/jmv.25720.

Yixuan, et al. (2020). Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. *J Med Virol*, 1–9.

Yong, S., Lin, T., Xiaomei, D., Hua, W., Yueshan, L., & Rangbing, W. (2020). Epidemiological and clinical characteristics of a familial cluster of COVID-19. *Epidemiol Infect,* 148: e145.

Yue, L. (2016). *How to Determine the Validity and Reliability of an Instrument.*

Zhou, et al. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*.

Zhou, et al. (2020). Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia. *Signal Transduct Target Ther,* 5 :18.

Prime Ministry Rwanda, "Public Notice from the Office of the Prime Minister on Coronavirus Disease 2019.pdf."

Tau Liu et al, 2020 vol.9 Risk factors associated with COVID-19 infection: a retrospective cohort study based on contacts tracing